NO2356135T3 - - Google Patents

Info

Publication number
NO2356135T3
NO2356135T3 NO09752598A NO09752598A NO2356135T3 NO 2356135 T3 NO2356135 T3 NO 2356135T3 NO 09752598 A NO09752598 A NO 09752598A NO 09752598 A NO09752598 A NO 09752598A NO 2356135 T3 NO2356135 T3 NO 2356135T3
Authority
NO
Norway
Application number
NO09752598A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2356135T3 publication Critical patent/NO2356135T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
NO09752598A 2008-11-05 2009-11-04 NO2356135T3 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11148508P 2008-11-05 2008-11-05
PCT/US2009/063268 WO2010053986A1 (en) 2008-11-05 2009-11-04 Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease

Publications (1)

Publication Number Publication Date
NO2356135T3 true NO2356135T3 (sv) 2018-03-24

Family

ID=41571714

Family Applications (1)

Application Number Title Priority Date Filing Date
NO09752598A NO2356135T3 (sv) 2008-11-05 2009-11-04

Country Status (21)

Country Link
US (2) US8563001B2 (sv)
EP (1) EP2356135B1 (sv)
JP (1) JP2012508174A (sv)
KR (1) KR20110081282A (sv)
CN (2) CN107050442B (sv)
AR (1) AR074273A1 (sv)
AU (1) AU2009313615B2 (sv)
BR (1) BRPI0921286B8 (sv)
CA (1) CA2741691C (sv)
CO (1) CO6382162A2 (sv)
DK (1) DK2356135T3 (sv)
ES (1) ES2648231T3 (sv)
IL (1) IL212491A0 (sv)
MX (1) MX2011004755A (sv)
NO (1) NO2356135T3 (sv)
NZ (2) NZ592368A (sv)
PE (1) PE20120116A1 (sv)
RU (1) RU2478396C2 (sv)
TW (1) TW201022442A (sv)
WO (1) WO2010053986A1 (sv)
ZA (1) ZA201102894B (sv)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2356135B1 (en) * 2008-11-05 2017-10-25 Wyeth LLC Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
TWI598360B (zh) * 2016-12-19 2017-09-11 義守大學 Ｆｓｂｍ重組蛋白及其用途
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152411A (en) 1977-07-27 1979-05-01 Akzona Incorporated High specific activity labeled substances
CA1133829A (en) 1978-08-24 1982-10-19 Neil J.L. Gilmour Pasteurellosis vaccines
US4837151A (en) 1980-05-19 1989-06-06 The Board Of Trustees Of The Leland Stanford Junior University, Stanford University Live vaccines comprising two mutations and foreign antigen
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US5097020A (en) 1983-07-05 1992-03-17 The University Of Rochester Immunogenic conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4454121A (en) 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4784948A (en) 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
US4695562A (en) 1984-04-06 1987-09-22 Univ. Of Tennessee Research Corp. Synthetic peptide compounds
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8424757D0 (en) 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US4720489A (en) 1984-10-15 1988-01-19 Douglas Shander Hair growth modification with ornithine decarboxylase inhibitors
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4772584A (en) 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
IT1216262B (it) 1986-09-02 1990-02-22 Bargellini Andrea Assorbente,ed utensile cosi'procedimento ed attrezzatura per la realizzato. formazione di un utensile di pulizia a strisce di materiale
EP0272929B1 (en) 1986-12-24 1996-03-20 Genentech, Inc. Enkephalinase for therapeutic use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5162226A (en) 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5124153A (en) 1987-08-24 1992-06-23 University Of Tennessee Research Corp. Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
AU3069189A (en) 1988-02-05 1989-08-25 Trustees Of Columbia University In The City Of New York, The Retroviral packaging cell lines and processes of using same
AU630093B2 (en) 1988-03-25 1992-10-22 Rockefeller University, The Synthetic peptides from streptococcal m protein and vaccines prepared therefrom
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5354844A (en) 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
SE9002212D0 (sv) 1990-06-21 1990-06-21 Hightech Receptor Ab Igg binding protein
JP3126381B2 (ja) 1990-07-31 2001-01-22 ジェネンテク，インコーポレイテッド 減少されたクリアランスを有する組織プラスミノーゲンアクチベーター変異体
WO1992005263A1 (en) 1990-09-25 1992-04-02 Cantab Pharmaceuticals Research Limited Viral defective vaccine produced by transcomplementing cell line
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
IL101715A (en) 1991-05-02 2005-06-19 Amgen Inc Recombinant dna-derived cholera toxin subunit analogs
US6100380A (en) 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
EP0672123A1 (en) 1992-01-08 1995-09-20 The Rockefeller University Multifunctional surface protein of streptococci
WO1993018157A1 (en) 1992-03-09 1993-09-16 The Regents Of The University Of California Compositions and methods for the identification and synthesis of sialyltransferases
WO1993021220A1 (en) 1992-04-08 1993-10-28 The Council Of The Queensland Institute Of Medical Research Synthetic peptides useful in a vaccine against and in the diagnosis of streptococcal infection
AU5128593A (en) 1992-09-16 1994-04-12 University Of Tennessee Research Corporation, The Antigen of hybrid m protein and carrier for group a streptococcal vaccine
WO1994006421A1 (en) 1992-09-16 1994-03-31 The University Of Tennessee Research Corporation Recombinant multivalent m protein vaccine
EP0673431A1 (en) 1992-12-03 1995-09-27 Genzyme Corporation Gene therapy for cystic fibrosis
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU696336B2 (en) 1993-03-19 1998-09-10 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. HSV) as vaccine
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
CA2144040A1 (fr) 1993-07-13 1995-01-26 Michel Perricaudet Vecteurs adenoviraux defectifs et utilisation en therapie genique
EP0711354A1 (en) 1993-07-30 1996-05-15 University Of Medicine & Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
FR2714830B1 (fr) 1994-01-10 1996-03-22 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2715847B1 (fr) 1994-02-08 1996-04-12 Rhone Poulenc Rorer Sa Composition contenant des acides nucléiques, préparation et utilisations.
FR2716459B1 (fr) 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU2194895A (en) 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
CA2187818A1 (en) 1994-04-15 1995-10-26 Robert W. Overell Gene delivery fusion proteins
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5866135A (en) 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5679654A (en) 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5837533A (en) 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
FR2727679B1 (fr) 1994-12-05 1997-01-03 Rhone Poulenc Rorer Sa Nouveaux agents de transfection et leurs applications pharmaceutiques
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
FR2730637B1 (fr) 1995-02-17 1997-03-28 Rhone Poulenc Rorer Sa Composition pharmaceutique contenant des acides nucleiques, et ses utilisations
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
AU6043396A (en) 1995-06-05 1996-12-24 University Of Alabama At Birmingham Research Foundation, The Composition and methods for creating syngeneic recombinant v irus-producing cells
FR2741358B1 (fr) 1995-11-17 1998-01-02 Centre Nat Rech Scient Production de vecteurs retroviraux par l'intermediaire de vecteurs viraux a base de virus a adn
US5846547A (en) 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US5829302A (en) 1996-05-31 1998-11-03 The National Machinery Company Cassette tooling
IT1289387B1 (it) 1996-07-16 1998-10-02 Zanussi Elettromecc Perfezionamenti ai circuiti refrigeranti a compressione per apparecchi domestici e simili
AU4427897A (en) 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
CZ299473B6 (cs) 1997-06-30 2008-08-06 Rhone-Poulenc Rorer S. A. Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva
JP2002515816A (ja) 1997-06-30 2002-05-28 アバンテイス・フアルマ・エス・アー ｉｎ ｖｉｖｏ組織に核酸ベクターを最適に電気導入する装置
BR9810372A (pt) 1997-06-30 2000-09-05 Rhone Poulenc Rorer Sa Processo de transferência de ácido nucléico para o interior de células de organismos eucarióticos pluricelulares in vivo, composição, ácido nucléico e campo elétrico, e, produto de combinação
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE69937571T2 (de) 1998-09-30 2008-09-04 The Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutiertes cholera holotoxin als hilfsmittel
US6168911B1 (en) 1998-12-18 2001-01-02 Eastman Kodak Company Formulations for preparing metal oxide-based pigment-binder transparent electrically conductive layers
WO2000037648A1 (en) 1998-12-22 2000-06-29 The University Of Tennessee Research Corporation Protective antigen of group a streptococci (spa)
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
US7256265B2 (en) 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
MXPA03003690A (es) * 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
JP2004533236A (ja) * 2001-04-13 2004-11-04 ワイエス 化膿性連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｙｏｇｅｎｅｓ）の表面タンパク質
JP2006520202A (ja) * 2003-03-04 2006-09-07 インターツェル・アクチェンゲゼルシャフト ストレプトコッカス・ピオゲネス抗原
CN100579985C (zh) * 2003-05-07 2010-01-13 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
EP1648500B1 (en) * 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
RU2263143C2 (ru) * 2004-01-05 2005-10-27 ГНУ Научно-исследовательский институт пушного звероводства и кролиководства им. В.А. Афанасьева Штамм бактерий streptococcus pyogenes №289, используемый для изготовления вакцин против стрептококкоза пушных зверей
JP2007520718A (ja) 2004-02-06 2007-07-26 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 治療可能性のあるアドヘシンおよびアドヘシン様タンパク質を同定するためのコンピュータを利用した方法
AU2005258397A1 (en) * 2004-07-01 2006-01-12 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
CN103360485A (zh) * 2004-08-18 2013-10-23 诺瓦生命科学有限公司 包含含有精氨酸和/或赖氨酸的基序的抗微生物肽
EP1807446A2 (en) * 2004-10-08 2007-07-18 Novartis Vaccines and Diagnostics, Inc. Immunogenic and therapeutic compositions for streptococcus pyogenes
EP1838317A4 (en) 2005-01-05 2012-02-29 Univ Minnesota ANALGESIC CONJUGATES
US7531541B2 (en) 2005-09-20 2009-05-12 Vanderbilt University Partial mGluR5 antagonists for treatment of anxiety and CNS disorders
EP2303317A2 (en) 2008-06-20 2011-04-06 Wyeth LLC Compositions and methods of use of orf 554 from beta hemolytic streptococcal strains
WO2009155484A2 (en) 2008-06-20 2009-12-23 Wyeth Compositions and methods of use of orf1358 from beta-hemolytic streptococcal strains
EP2356135B1 (en) * 2008-11-05 2017-10-25 Wyeth LLC Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease

Also Published As

Publication number Publication date
ZA201102894B (en) 2012-06-27
MX2011004755A (es) 2011-10-10
US8563001B2 (en) 2013-10-22
AU2009313615B2 (en) 2012-11-29
CN107050442B (zh) 2022-09-13
AR074273A1 (es) 2011-01-05
NZ592368A (en) 2013-11-29
IL212491A0 (en) 2011-06-30
CN107050442A (zh) 2017-08-18
EP2356135A1 (en) 2011-08-17
RU2478396C2 (ru) 2013-04-10
TW201022442A (en) 2010-06-16
RU2011116286A (ru) 2012-12-20
KR20110081282A (ko) 2011-07-13
BRPI0921286B1 (pt) 2021-11-23
US20100119534A1 (en) 2010-05-13
AU2009313615A1 (en) 2010-05-14
BRPI0921286A8 (pt) 2018-01-02
NZ614064A (en) 2015-04-24
WO2010053986A1 (en) 2010-05-14
BRPI0921286B8 (pt) 2022-10-25
PE20120116A1 (es) 2012-02-18
BRPI0921286A2 (pt) 2015-03-24
EP2356135B1 (en) 2017-10-25
US9127050B2 (en) 2015-09-08
CO6382162A2 (es) 2012-02-15
CA2741691A1 (en) 2010-05-14
ES2648231T3 (es) 2017-12-29
CN102203122A (zh) 2011-09-28
DK2356135T3 (en) 2017-12-04
US20140037669A1 (en) 2014-02-06
JP2012508174A (ja) 2012-04-05
CA2741691C (en) 2019-11-26

Similar Documents

Publication Publication Date Title
BR112016019572A2 (sv)
BRPI0909040A2 (sv)
BRPI0917573A2 (sv)
BRPI0908549B8 (sv)
BRPI0918697A2 (sv)
BRPI0917525A2 (sv)
BRPI0920750A2 (sv)
BRPI0919470A2 (sv)
BRPI0922455A2 (sv)
BRPI0907698A2 (sv)
BRPI0917618A8 (sv)
BRPI0923734A2 (sv)
BRPI0912727A2 (sv)
BRPI0908285A2 (sv)
BRPI0910485A2 (sv)
BRPI0914750A2 (sv)
BRPI0922669A2 (sv)
BRPI0908120A2 (sv)
BRPI0912462A2 (sv)
BRPI0915616A2 (sv)
BRPI0904541A8 (sv)
BRPI0919811A2 (sv)
BRPI0920914A2 (sv)
BRPI0922550A2 (sv)
BRPI0916284A2 (sv)